Green Elephant Biotech has introduced Archimedes One, the pioneer in a new category of “Dynamic Adherent Bioreactors.” The system is designed to overcome a long-standing challenge in the industry: scaling up adherent cell processes without compromising biological integrity or adding unnecessary complexity.
Innovations in cultivation and harvesting Instead of forcing adherent cells into suspension or utilizing intricate matrices, Archimedes One enables a controlled, perfusion-based adherent culture environment. Key technical advantages include:
-
Smart monitoring: The platform features integrated process monitoring and automated harvesting, replacing traditional manual detachment steps that often lead to inconsistency.
-
High compatibility: The system works with standard biocontrollers to manage parameters such as pH, dissolved oxygen, and temperature, eliminating the need for custom subsystems or conditioning vessels.
-
Operational efficiency: By combining the familiarity of 2D culture with the precision of a bioreactor, Archimedes One supports improved reproducibility and provides a clearer path for technology transfer between manufacturing sites.
Commercial roadmap and Early Access Program Leadership at Green Elephant Biotech emphasized that manufacturing should not require a choice between biological quality and industrial scalability.
Alongside the market introduction, the company has launched an Early Access Program for selected cell therapy firms and CDMOs. Participants will gain priority access to production units and dedicated technical support, contributing to essential application data and case studies ahead of the full commercial launch scheduled for later this year.